Phase II Study of TSR-022 in Combination With TSR-042 for the Treatment of Advanced Hepatocellular Carcinoma
Phase of Trial: Phase II
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs Cobolimab (Primary) ; Dostarlimab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 06 Nov 2019 Status changed from not yet recruiting to recruiting.
- 23 Sep 2019 Planned End Date changed from 1 Oct 2022 to 1 Oct 2023.
- 23 Sep 2019 Planned primary completion date changed from 1 Oct 2021 to 1 Oct 2022.